Implementation planning for lung cancer screening: five major challenges

Affiliations

¹ Roy Castle Lung Cancer Research Programme, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, L7 8TX Liverpool, UK. Electronic address: j.k.field@liverpool.ac.uk.
² Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
³ Royal Brompton and Harefield NHS Foundation Trust, Imperial College, London, UK.
⁴ Nottingham University Hospitals and Respiratory Medicine Unit, David Evans Centre, Nottingham City Hospital Campus, University of Nottingham, Nottingham, UK.

Comment

John K Field et al. Lancet Respir Med. 2016 Sep.

. 2016 Sep;4(9):685-687.

doi: 10.1016/S2213-2600(16)30233-8.

¹ Roy Castle Lung Cancer Research Programme, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, L7 8TX Liverpool, UK. Electronic address: j.k.field@liverpool.ac.uk.
² Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
³ Royal Brompton and Harefield NHS Foundation Trust, Imperial College, London, UK.
⁴ Nottingham University Hospitals and Respiratory Medicine Unit, David Evans Centre, Nottingham City Hospital Campus, University of Nottingham, Nottingham, UK.

No abstract available

Comment on

Lung cancer screening: latest developments and unanswered questions.
van der Aalst CM, Ten Haaf K, de Koning HJ. van der Aalst CM, et al. Lancet Respir Med. 2016 Sep;4(9):749-761. doi: 10.1016/S2213-2600(16)30200-4. Lancet Respir Med. 2016. PMID: 27599248 Review.